Implementation of the Inflation Reduction Act. Issues related to Medicare Part D redesign's impact on low-income subsidy beneficiaries. Issues related to prior authorization, open access, and medication step therapy; The Safe Step Act (HR 5509/S. 2903)
2026 · 3rd Quarter (July 1 - Sep 30)
OTSUKA AMERICA PHARMACEUTICAL, INC.
Filed by OTSUKA AMERICA PHARMACEUTICAL, INC..
Open official filingSource-reported fields
Filing overview
- Type
- 3rd Quarter - Report
- Posted
- Oct 15, 2026
- Income
- Not reported
- Expenses
- $310,000.00
- Registrant
- OTSUKA AMERICA PHARMACEUTICAL, INC.
- Filing UUID
- 57eddf43-e3f1-4cf9-a2a6-8cf8998071bb
- Termination date
- Not reported
Expense method: A
Literal source text
Lobbying issues and bill citations
Issues relating to early detection of PTSD, mental health parity and coordinated care and mental health equity. PBM reform. Issues related to rare nephrology/kidney diseases, 340B reform, psychedelics treatments for PTSD and mental health. H.R. 1518, the New Era of Preventing End-Stage Kidney Disease Act. Issues related to drug pricing, foreign reference pricing, biomedical research, and pharmaceutical supply chain.
Literal federal measure citations: H.R. 1518
Appropriations for the Department of Health & Human Services and the Department of Veterans Affairs, and Department of Defense.
Health care policies relating to mental health and PTSD, including authorizations and appropriations for the Department of Veterans Affairs related to mental health and PTSD.
Issues related to tariffs on pharmaceuticals and pharmaceutical supply chain.
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.